CLINICAL TRIALS PROFILE FOR ARANESP
✉ Email this page to a colleague
All Clinical Trials for ARANESP
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00093015 ↗ | Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) | Completed | Amgen | Phase 3 | 2004-08-01 | The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus. Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD |
| NCT00111995 ↗ | Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis | Completed | Amgen | Phase 4 | 2002-05-01 | This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile. |
| NCT00116701 ↗ | Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis | Completed | Amgen | Phase 3 | 2005-05-01 | Treatment period 1:To demonstrate that switching HD subjects with a baseline haemoglobin (Hb) ≥ 10 g/dL and ≤ 13 g/dL from either subcutaneous (SC) or intravenous (IV) rHuEPO to IV darbepoetin alfa results in a mean Hb > 11 g/dL. Treatment Period 2:To demonstrate that switching subjects with a Hb > 11 g/dL and ≤ 13 g/dL from once weekly IV darbepoetin alfa to once every 2 weeks (Q2W) maintains the mean Hb at > 11 g/dL. |
| NCT00117039 ↗ | A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia | Completed | Amgen | Phase 4 | 2004-01-01 | The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network (NCCN) guidelines). |
| NCT00117065 ↗ | Study of Transplant Related Anemia Treated With Aranesp® (STRATA) | Completed | Amgen | Phase 4 | 1969-12-31 | The purpose of this study was to evaluate Aranesp® administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients. |
| NCT00117078 ↗ | Aranesp® Monthly Preference Study - 2 | Completed | Amgen | Phase 4 | 1969-12-31 | The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW). |
| NCT00117104 ↗ | Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis | Completed | Amgen | Phase 4 | 1969-12-31 | The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or subjects converted from rHuEPO therapy administered IV thrice weekly (TIW). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARANESP
Condition Name
Clinical Trial Locations for ARANESP
Trials by Country
Clinical Trial Progress for ARANESP
Clinical Trial Phase
Clinical Trial Sponsors for ARANESP
Sponsor Name
